IL-17 ANTIBODY FORMULATION

The present invention provides stabilized pharmaceutical formulations for anti-IL-17 antibodies, comprising e.g. citrate, sodium chloride and polysorbate-80 at pH 5.7. These stabilized anti-IL-17 antibody pharmaceutical formulations can be used to treat rheumatoid arthritis, psoriasis, ankylosing sp...

Full description

Saved in:
Bibliographic Details
Main Authors VINCENT JOHN CORVARI, PATRICK DANIEL DONOVAN, BARBARA ANN WILLIAMS, AARON PAUL MARKHAM
Format Patent
LanguageEnglish
Spanish
Published 14.04.2015
Subjects
CHEMISTRY
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PEPTIDES
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
Online AccessGet full text

Cover

More Information
Summary:The present invention provides stabilized pharmaceutical formulations for anti-IL-17 antibodies, comprising e.g. citrate, sodium chloride and polysorbate-80 at pH 5.7. These stabilized anti-IL-17 antibody pharmaceutical formulations can be used to treat rheumatoid arthritis, psoriasis, ankylosing spondilitis, psoriatic arthritis or multiple myeloma. La presente invención proporciona formulaciones farmacéuticas estabilizadas para anticuerpos anti-lL-17, comprendiendo, por ejemplo, citrato, cloruro de sodio y polisorbato-80 a pH 5.7. Estas formulaciones farmacéuticas de anticuerpo anti-IL-17 estabilizadas pueden ser usadas para tratar artritis reumatoide, psoriasis, espondilitis anquilosante, artritis psoriática o mieloma múltiple.
Bibliography:Application Number: MX20140010710